|
FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. |
|
|
Research Funding - Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha |
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst) |
|
|
|
Consulting or Advisory Role - Agios; AstraZeneca; Delcath Systems; Genoscience Pharma; Incyte; Ipsen; Keocyt; Merck; Novartis; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics |
Speakers' Bureau - Ipsen; Novartis |
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Celgene; Nucana |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Genentech/Roche; Target Pharmasolutions; Target Pharmasolutions (Inst) |
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Tekmira (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - AVEO; Gilead Sciences; GlaxoSmithKline |
Consulting or Advisory Role - Agios (Inst); ArQule (Inst); Celgene (Inst); Fujifilm (Inst); G1 Therapeutics; Halozyme (Inst); Inspyr Therapeutics; Insys Therapeutics (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TD2 |
Research Funding - Agios (Inst); ARIAD (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Celgene (Inst); Dicerna (Inst); Eisai (Inst); EMD Serono (Inst); Halozyme (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst) |
Travel, Accommodations, Expenses - ArQule; AstraZeneca; Celgene |
|
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; TTY Biopharm |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD; Novartis; Ono Pharmaceutical; PharmaEngine; SynCoreBio; TTY Biopharm |
Research Funding - Celgene (Inst); GlaxoSmithKline (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); SynCoreBio (Inst); TTY Biopharm (Inst) |
Patents, Royalties, Other Intellectual Property - anti-alpha-enolase (ENO-1) monoclonal antibody to HuniLife Technology, Taiwan |
|
Nataliya Volodymyrivna Uboha |
Consulting or Advisory Role - EMD Serono; Flatiron Health; Gerson Lehrman Group; Lilly |
Research Funding - EMD Serono (Inst); Taiho Pharmaceutical (Inst) |
|
|
Consulting or Advisory Role - Ipsen (Inst) |
Research Funding - Bayer; BTG; Exelixis; IBM; Ipsen; Sirtex Medical; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Ipsen |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Genentech |
Research Funding - Amgen; Bayer; BBI Healthcare; Bristol-Myers Squibb; Celgene; Five Prime Therapeutics; Forty Seven; Genentech; GlaxoSmithKline; Merck; Mirati Therapeutics; Novartis; Pfizer; Pharmacyclics |
|
|
Consulting or Advisory Role - Exelixis; Ipsen; Lexicon; Novartis |
Speakers' Bureau - Lexicon |
|
|
Honoraria - Fujifilm; Lilly; Nobelpharma; Novartis; Pfizer; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha |
Consulting or Advisory Role - Novartis; Taiho Pharmaceutical; Yakult Honsha |
Research Funding - Eisai (Inst); Nobelpharma (Inst); ONO PHARMACEUTICAL (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst) |
|
|
Employment - Taiho Pharmaceutical |
|
|
Honoraria - Merck Serono; SERVIER |
Consulting or Advisory Role - AstraZeneca; Basilea; Bayer; Incyte; Merck Serono; Merck Serono; Roche; SERVIER |
Speakers' Bureau - Amgen; Celgene |
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb/Medarex; Merck Serono; MSD Oncology; SERVIER |